Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | P2RY2 | P41231 | 8/20 | 0.62 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.55 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.55 |
| ▸ | ST6GAL1 | P15907 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.52 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.52 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6402546 | 0.94 | TSHR (0.65) | TSHRGLAP2RY2P2RY6P2RY4 | |
| Citicoline SCHEMBL14235352 | 0.94 | P2RY2 (0.70) | TSHRGLAP2RY2P2RY6P2RY4 | |
| Citicoline SCHEMBL13933086 | 0.94 | P2RY2 (0.70) | TSHRGLAP2RY2P2RY6P2RY4 | |
| Citicoline SCHEMBL29356848 | 0.94 | P2RY2 (0.70) | TSHRGLAP2RY2P2RY6P2RY4 | |
| Citicoline SCHEMBL8303928 | 0.94 | P2RY2 (0.70) | TSHRGLAP2RY2P2RY6P2RY4 | |
| SCHEMBL503812 | 0.92 | TSHR (0.68) | TSHRGLAP2RY2P2RY6P2RY4 | |
| Ammonia Solution, Strong SCHEMBL28018228 | 0.92 | TSHR (0.67) | TSHRGLAP2RY2P2RY6P2RY4 | |
| SCHEMBL27601953 | 0.92 | TSHR (0.72) | TSHRGLAP2RY2P2RY4ST6GAL1 | |
| Citicoline SCHEMBL4311534 | 0.91 | TSHR (0.76) | TSHRGLAP2RY2P2RY6P2RY4 | |
| Citicoline SCHEMBL25411862 | 0.91 | TSHR (0.76) | TSHRGLAP2RY2P2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3935961-A1 | PARENTERAL NUTRITION FORMULATIONS | Baxter International Inc (US) | 2022-01-12 | — | — | EP | claimed |
| US-20210212936-A1 | PARENTERAL NUTRITION FORMULATION | BAXTER HEALTHCARE SA (CH) | 2021-07-15 | — | — | US | claimed |
| EP-3801059-A1 | PARENTERAL NUTRITION FORMULATION | Baxter International Inc. (US) | 2021-04-14 | — | — | EP | claimed |
| US-20260090983-A1 | PARENTERAL NUTRITION FORMULATION | BAXTER INT (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4696296-A2 | PARENTERAL NUTRITION FORMULATION | BAXTER INTERNATIONAL INC. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20230263759-A1 | PARENTERAL NUTRITION FORMULATION | BAXTER HEALTHCARE SA (CH) | 2023-08-24 | — | — | US | disclosed |
| US-11666548-B2 | Parenteral nutrition formulation | BAXTER INTERNATIONAL INC. (US) | 2023-06-06 | — | — | US | disclosed |
| EP-4161486-A1 | PARENTERAL NUTRITION FORMULATION | Baxter International Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-3935961-A1 | PARENTERAL NUTRITION FORMULATIONS | Baxter International Inc (US) | 2022-01-12 | — | — | EP | disclosed |
| US-20210378998-A1 | Parenteral Nutrition Formulation | BAXTER INTERNATIONAL INC. | 2021-12-09 | — | — | US | disclosed |
| US-20210212936-A1 | PARENTERAL NUTRITION FORMULATION | BAXTER HEALTHCARE SA (CH) | 2021-07-15 | — | — | US | disclosed |
| EP-3801059-A1 | PARENTERAL NUTRITION FORMULATION | Baxter International Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| CN-112203530-A | Parenteral nutrition preparation | 巴克斯特国际公司 | 2021-01-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260090983-A1 | PARENTERAL NUTRITION FORMULATION | PHOSPHO1, PNLIP, PCTP | TSHR 3876/4885GLA 2410/4885P2RY2 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.